Groups: Investment

Alessandro Chiavari

Alessandro is a Capital Markets Analyst at Pura Vida. His areas of focus include trading and syndicate deals. Prior to joining in 2021, he served as a Business Analyst at McKinsey, where he served clients on a diverse set of projects, including corporate & investment bank digital strategy, venture capital fundraising, and post-merger integrations. Alessandro …

Alessandro Chiavari Read More »

Adi Gupta

Adi is a Principal at Pura Vida, specializing in private and crossover investments across the healthcare universe, with a focus on tools and diagnostics. Prior to joining in 2021, he spent 6 years as a Senior Engagement Manager at McKinsey, where he served life sciences, pharma/biotech and medical device clients and worked extensively with management …

Adi Gupta Read More »

Gerrel Olivier

Gerrel is Head of Pura Vida Pro. He previously served as an Analyst at Davidson Kempner Capital Management, a $36 billion multi-strategy hedge fund based in New York. At Davidson Kempner, he was one of five investment professionals on their US Long / Short public equity team, specializing in both large-cap Healthcare and Consumer Packaged …

Gerrel Olivier Read More »

Matt Newton

Matt is the Head of Equities at Pura Vida. Previously, he worked at Moore Capital Management, where he built out Moore Equity Strategies Americas (MESA), a diversified long/short equity team. This included formation of a 20-person, multi-manager investment team that managed just under $3 billion gross including a best ideas portfolio he co-managed. Prior to …

Matt Newton Read More »

Brian Kwak

Brian is a Senior Analyst at Pura Vida. He previously served as a Senior Consultant and Project Manager at Siemens, specializing in management consulting and financial advisory. Brian received a B.S. in Finance and Mathematics from University of Notre Dame and an M.B.A from Columbia Business School, where he was active in the Heilbrunn Center …

Brian Kwak Read More »

Jon Helander, PhD

Jon is a Therapeutics Analyst at Pura Vida. Prior to joining Pura Vida in 2020, he worked as a biotech associate at JMP Securities and Deutsche Bank. He has worked on numerous academic programs in developing small molecule therapeutics for multiple diseases and in collaboration with private biotechnology companies as well as in applications for …

Jon Helander, PhD Read More »

Doris Ting Heffernan

Doris is Managing Director specializing in private investments at Pura Vida. Prior to joining in 2019, she served as Senior Vice President of Sales Operations and Revenue Strategy at iHeartMedia, Inc. (formerly Clear Channel Communications, Inc.) the nation’s largest owner and operator of radio stations. At iHeartMedia, she led a team responsible for supporting and …

Doris Ting Heffernan Read More »

Tae-Il Ha

Tae-Il is a Senior Analyst at Pura Vida, focused on medical devices and technologies. Prior to joining in 2018, he was a Senior Associate at Baring Private Equity Asia, one of the largest private alternative investment firms in Asia. He started his career as an Analyst at Citigroup’s Asia TMT team in its global investment …

Tae-Il Ha Read More »

Beau Bassett

Beau is Head of Therapeutics at Pura Vida, where he leads idea generation for the therapeutics subsectors and works with Efrem Kamen on risk management decisions for the therapeutics subsectors. Prior to re-joining the firm in 2017, Beau was the Senior Analyst for the drug portfolio at Passaic, a healthcare dedicated pod at Millennium. On …

Beau Bassett Read More »

Frank Litvack, MD

Frank is a co-founder of Pura Vida Investments and serves as Member, Director of Designated Investments. Frank has an extensive background in healthcare ranging from clinical practice and research to founding and operating companies. He currently serves as CEO of Vida FLaSH Acquisitions, Inc., a life sciences SPAC as well as co-managing member of FLaSH …

Frank Litvack, MD Read More »

Scroll to Top